Erratum to modulation of in situ estrogen synthesis by proline-, Glutamic Acid-, and Leucine-Rich protein-1: Potential estrogen receptor autocrine signaling loop in breast cancer cells (Mol Endocrinol, (2008), 22, (649-664), 10.1210/me.2007-0350);Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: Potential estrogen receptor autocrine signaling loop in breast cancer cells

Molecular Endocrinology

Volumn 22, Issue 3, 2008, Pages 649-664

  Rajhans, Rajib ^a   Nair, Hareesh B ^a   Nair, Sujit S ^a   Cortez, Valerie ^a   Ikuko, Kijima ^b   Kirma, Nameer B ^a   Zhou, Dujin ^c   Holden, Alan E ^a   Brann, Darrell W ^c   Chen, Shiuan ^b   Tekmal, Rajeshwar Rao ^a   Vadlamudi, Ratna K ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; ESTROGEN; ESTROGEN RECEPTOR; GLUTAMIC ACID; LEUCINE; PROLINE; PROLINE GLUTAMIC ACID AND LEUCINE RICH PROTEIN 1; PROTEIN; TRITIUM OXIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CARCINOMA IN SITU; CELL STRAIN MCF 7; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ESTROGEN SYNTHESIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH; UPREGULATION; XENOGRAFT;

EID: 40849094564     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2012-1367     Document Type: Erratum

References (59)

1. Moy B, Goss PE 2006 Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches. Clin Cancer Res 12:4790-4793
2. McDonnell DP, Norris JD 2002 Connections and regulation of the human estrogen receptor. Science 296:1642-1644
3. Jensen EV, Jordan VC 2003 The estrogen receptor: a model for molecular medicine. Clin Cancer Res 9:1980-1989
4. Losel R, Wehling M 2003 Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol 4:46-56
5. Bjornstrom L, Sjoberg M 2005 Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 19:833-842
6. Lonard DM, O'Malley BW 2006 The expanding cosmos of nuclear receptor coactivators. Cell 125:411-414
7. Collingwood TN, Urnov FD, Wolffe AP 1999 Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription. J Mol Endocrinol 23:255-275
8. Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM, Graham-Lorence S, Amarneh B, Ito Y, Fisher CR, Michael MD 1994 Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 15:342-355
9. Lu Q, Nakmura J, Savinov A, Yue W, Weisz J, Dabbs DJ, Wolz G, Brodie A 1996 Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers. Endocrinology 137:3061-3068
10. James VH, McNeill JM, Lai LC, Newton CJ, Ghilchik MW, Reed MJ 1987 Aromatase activity in normal breast and breast tumor tissues: in vivo and in vitro studies. Steroids 50:269-279
11. Bulun SE, Sebastian S, Takayama K, Suzuki T, Sasano H, Shozu M 2003 The human CYP19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters. J Steroid Biochem Mol Biol 86:219-224
12. Jordan VC, Brodie AM 2007 Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 72:7-25
13. Kaklamani VG, Gradishar WJ 2005 Adjuvant therapy of breast cancer. Cancer Invest 23:548-560
14. Pietras RJ 2006 Biologic basis of sequential and combination therapies for hormone-responsive breast cancer. Oncologist 11:704-717
15. Sabnis G, Goloubeva O, Jelovac D, Schayowitz A, Brodie A 2007 Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens. Clin Cancer Res 13:2751-2757
16. Vadlamudi RK, Wang RA, Mazumdar A, Kim Y, Shin J, Sahin A, Kumar R 2001 Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor α. J Biol Chem 276:38272-38279
17. Wong CW, McNally C, Nickbarg E, Komm BS, Cheskis BJ 2002 Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci USA 99:14783-14788
18. Vadlamudi RK, Kumar R 2007 Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR. Nucl Recept Signal 5:e004
19. Balasenthil S, Vadlamudi RK 2003 Functional interactions between the estrogen receptor coactivator PELP1/MNAR and retinoblastoma protein. J Biol Chem 278:22119-22127
20. Nair SS, Mishra SK, Yang Z, Balasenthil S, Kumar R, Vadlamudi RK 2004 Potential role of a novel transcriptional coactivator PELP1 in histone H1 displacement in cancer cells. Cancer Res 64:6416-6423
21. Rajhans R, Nair S, Holden AH, Kumar R, Tekmal RR, Vadlamudi RK 2007 Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucinerich protein 1/modulator of the nongenomic actions of the estrogen receptor. Cancer Res 67:5505-5512
22. Sirianni R, Chimento A, Malivindi R, Mazzitelli I, Andò S, Pezzi V 2007 Insulin-like growth factor-I, regulating aromatase expression through steroidogenic factor 1, supports estrogen-dependent tumor Leydig cell proliferation. Cancer Res 67:8368-8377
23. Sasano H, Edwards DP, Anderson TJ, Silverberg SG, Evans DB, Santen RJ, Ramage P, Simpson ER, Bhatnagar AS, Miller WR 2003 Validation of new aromatase monoclonal antibodies for immunohistochemistry: progress report. J Steroid Biochem Mol Biol 86:239-244
24. Sasano H, Anderson TJ, Silverberg SG, Santen RJ, Conway M, Edwards DP, Krause A, Bhatnagar AS, Evans DB, Miller WR 2005 The validation of new aromatase monoclonal antibodies for immunohistochemistry: a correlation with biochemical activities in 46 cases of breast cancer. J Steroid Biochem Mol Biol 95:35-39
25. Wang X, Chen S 2006 Aromatase destabilizer: novel action of exemestane, a food and drug administration-approved aromatase inhibitor. Cancer Res 66:10281-10286
26. Zhou DJ, Pompon D, Chen SA 1990 Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res 50:6949-6954
27. Vadlamudi RK, Balasenthil S, Broaddus RR, Gustafsson JA, Kumar R 2004 Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor in human endometrial tumors. J Clin Endocrinol Metab 89:6130-6138
28. Subbaramaiah K, Howe LR, Port ER, Brogi E, Fishman J, Liu CH, Hla T, Hudis C, Dannenberg AJ 2006 HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism. Cancer Res 66:5504-5511
29. Klinghoffer RA, Sachsenmaier C, Cooper JA, Soriano P 1999 Src family kinases are required for integrin but not PDGFR signal transduction. EMBO J 18:2459-2471
30. Yang C, Yu B, Zhou D, Chen S 2002 Regulation of aromatase promoter activity in human breast tissue by nuclear receptors. Oncogene 21:2854-2863
31. Zhou D, Chen S 2001 PNRC2 is a 16 kDa coactivator that interacts with nuclear receptors through an SH3-binding motif. Nucleic Acids Res 29:3939-3948
32. Zhou D, Ye JJ, Li Y, Lui K, Chen S 2006 The molecular basis of the interaction between the proline-rich SH3-binding motif of PNRC and estrogen receptor α. Nucleic Acids Res 34:5974-5986
33. Liu D, Hinshelwood MM, Giguere V, Mendelson CR 2006 Estrogen related receptor-αenhances surfactant protein-A gene expression in fetal lung type II cells. Endocrinology 147:5187-5195
34. Miller WR, Anderson TJ, Jack WJ 1990 Relationship between tumour aromatase activity, tumour characteristics and response to therapy. J Steroid Biochem Mol Biol 37:1055-1059
35. Shin I, Miller T, Arteaga CL 2006 ErbB receptor signaling and therapeutic resistance to aromatase inhibitors. Clin Cancer Res 12:1008s-1012s
36. Ghosh S, Lu Y, Katz A, Hu Y, Li R 2007 Tumor suppressor BRCA1 inhibits a breast cancer-associated promoter of the aromatase gene (CYP19) in human adipose stromal cells. Am J Physiol Endocrinol Metab 292:E246-E252
37. Lu M, Chen D, Lin Z, Reierstad S, Trauernicht AM, Boyer TG, Bulun SE 2006 BRCA1 negatively regulates the cancer-associated aromatase promoters I.3 and II in breast adipose fibroblasts and malignant epithelial cells. J Clin Endocrinol Metab 91:4514-4519
38. Yang C, Zhou D, Chen S 1998 Modulation of aromatase expression in the breast tissue by ERRα-1 orphan receptor. Cancer Res 58:5695-5700
39. Mishra SK, Mazumdar A, Vadlamudi RK, Li F, Wang RA, Yu W, Jordan VC, Santen RJ, Kumar R 2003 MICoA, a novel metastasis-associated protein 1 (MTA1) interacting protein coactivator, regulates estrogen receptor-α transactivation functions. J Biol Chem 278:19209-19219
40. Bulun SE, Price TM, Aitken J, Mahendroo MS, Simpson ER 1993 A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J Clin Endocrinol Metab 77:1622-1628
41. Bulun SE, Lin Z, Imir G, Amin S, Demura M, Yilmaz B, Martin R, Utsunomiya H, Thung S, Gurates B, Tamura M, Langoi D, Deb S 2005 Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev 57:359-383
42. Simpson ER, Clyne C, Rubin G, Boon WC, Robertson K, Britt K, Speed C, Jones M 2002 Aromatase: a brief overview. Annu Rev Physiol 64:93-127
43. Smith CL, O'Malley BW 2004 Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25:45-71
44. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS 1997 AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277:965-968
45. Barnes CJ, Vadlamudi RK, Kumar R 2004 Novel estrogen receptor coregulators and signaling molecules in human diseases. Cell Mol Life Sci 61:281-291
46. Schiff R, Massarweh SA, Shou J, Bharwani L, Arpino G, Rimawi M, Osborne CK 2005 Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol 56(Suppl 1):10-20
47. Stein RA, McDonnell DP 2006 Estrogen-related receptor α as a therapeutic target in cancer. Endocr Relat Cancer 13(Suppl 1):S25-S32
48. Chen S, Itoh T, Wu K, Zhou D, Yang C 2002 Transcriptional regulation of aromatase expression in human breast tissue. J Steroid Biochem Mol Biol 83:93-99
49. Miki Y, Suzuki T, Tazawa C, Yamaguchi Y, Kitada K, Honma S, Moriya T, Hirakawa H, Evans DB, Hayashi S, Ohuchi N, Sasano H 2007 Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells. Cancer Res 67:3945-3954
50. Zhou D, Quach KM, Yang C, Lee SY, Pohajdak B, Chen S 2000 PNRC: a proline-rich nuclear receptor coregulatory protein that modulates transcriptional activation of multiple nuclear receptors including orphan receptors SF1 (steroidogenic factor 1) and ERRα1 (estrogen related receptor α-1). Mol Endocrinol 14:986-998
51. Gururaj AE, Rayala SK, Vadlamudi RK, Kumar R 2006 Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations. Clin Cancer Res 12:1001s-1007s
52. Marcom PK, Isaacs C, Harris L, Wong ZW, Kommarreddy A, Novielli N, Mann G, Tao Y, Ellis MJ 2007 The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 102:43-49
53. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R 2004 Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96:926-935
54. Manavathi B, Nair SS, Wang RA, Kumar R, Vadlamudi RK 2005 Proline-, glutamic acid-, and leucine-rich protein-1 is essential in growth factor regulation of signal transducers and activators of transcription 3 activation. Cancer Res 65:5571-5577
55. Trevino JG, Summy JM, Gallick GE 2006 SRC inhibitors as potential therapeutic agents for human cancers. Mini Rev Med Chem 6:681-687
56. Russello SV, Shore SK 2004 SRC in human carcinogenesis. Front Biosci 9:139-144
57. Vadlamudi RK, Manavathi B, Balasenthil S, Nair SS, Yang Z, Sahin AA, Kumar R 2005 Functional implications of altered subcellular localization of PELP1 in breast cancer cells. Cancer Res 65:7724-7732
58. Barletta F, Wong CW, McNally C, Komm BS, Katzenellenbogen B, Cheskis BJ 2004 Characterization of the interactions of estrogen receptor and MNAR in the activation of cSrc. Mol Endocrinol 18:1096-1108
59. Zhou D, Chen S 1999 Identification and characterization of a cAMP-responsive element in the region upstream from promoter 1.3 of the human aromatase gene. Arch Biochem Biophys 371:179-190